November 25, 2024
Centauri is excited to announce that we have been selected to receive a £1M grant under the first round of @PACE-AMR funding which will support the continued development of our novel immunotherapeutic platform. Founded in 2023 by LifeArc, Innovate UK and Medicines Discovery Catapult, PACE is a new and comprehensive approach to tackling one of the world’s most complex health challenges: antimicrobial resistance (AMR). We are proud of the team’s efforts to progress this platform and excited to expand our pipeline with this additional funding from PACE.
Full PR available here